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In 2009, NEWMEDS (Novel Methods leading to New
Medications in Depression and Schizophrenia) became one of the first projects to be selected for the European Innovative Medicines Initiative (IMI), a €2-billion publicprivate partnership funded by the European Union and members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) to address bottlenecks in drug development. Overall, NEWMEDS aimed to address the major need for new treatments for psychiatric disorders such as schizophrenia, for which there have been very few really innovative treatments for many years, despite much basic research and substantial investment by pharmaceutical companies in drug development.
The project was established as a consortium of seven leading European academic institutions (with expertise in preclinical and clinical models) and two biotech companies (with expertise in high-throughput genetics, transcriptomics and proteomics) partnered, initially, with twelve larger EFPIA-affiliated pharmaceutical companies. It was financed with €11 million for academic partners during 2009-2015, matched by the equivalent sum invested by EFPIA partners as 'in kind' contributions (such as in-house research), making it the biggest psychiatry consortium to date, with a unique blend of academia and industry perspectives and expertise.
NEWMEDS was structured in nine overlapping work packages (WPs) to facilitate its organization and management. WP1, 2 and 4 focused on improving the translatability of animal models of psychiatric disorders; WP4, 5 and 6 focused on experimental tools to enable early decision-making in human studies; WP3, 7, 8 and 9 focused on the way clinical trials are conducted and WP7 and 9 focused on biologically validated targets. Precompetitive and competitive areas were clearly defined: the effects of publicly available drugs on key brain circuits and the technologies used to assess the effects were precompetitive, whereas drug discovery on specific targets and structure-activity studies were excluded from the scope of the consortium. This provided a fertile environment for scientists to openly discuss technical questions and work together towards standardizing technology. The academic partners proposed detailed projects in response to an industry-led call, fine-tuning the specific needs after discussion with industry colleagues, to ensure that the most relevant experiments were performed. This was enabled by excellent management put in place by the academic and industry leads, Shitij Kapur from King's College London (UK) and Tine Bryan Stensbøl from Lundbeck (Denmark). In this article, to illustrate the nature of the output of the consortium overall, we discuss the progress that was made through several WPs (1, 2 and 4) with aspects that converged on understanding of the brain circuits involved in psychiatric disorders.
Brain circuits and 'connectopathies'
The limited understanding of the pathophysiology of depression and schizophrenia has hampered the development of experimental models. This has been a major limitation for drug discovery for such dis orders, which has depended heavily on receptor-focused mechanisms based on first-generation antipsychotic and anti depressant drugs, discovered by serendipity more than 50 years ago. This has enabled the development of second-generation drugs based on the same pharmacological targets, such as the dopamine D 2 receptor in schizophrenia, but not breakthrough therapies.
As psychiatric disorders may be 'connectopathies' -disorders of neuronal connectivity -several WPs within NEWMEDS were framed to identify novel discovery paradigms to explicitly assess brain circuits involved in the pathophysiology and treatment of major depression and schizophrenia, using electrophysiology (WP1), behavioural paradigms (WP2 and 7) and translational neuroimaging (WP4).
At the initiation of NEWMEDS, the main aims relating to the understanding of brain circuits were to:
• harmonize the electrophysiological approach to animal models for schizophrenia and depression; and NEWMEDS* Despite the vast amount of research on schizophrenia and depression in the past two decades, there have been few innovative drugs to treat these disorders. Precompetitive research collaborations between companies and academic groups can help tackle this innovation deficit, as illustrated by the achievements of the IMI-NEWMEDS consortium.
• establish robust back-translation of resting state functional magnetic resonance imaging (rsfMRI) to measure functional connectivity in rodents and man (WP4); • link electrophysiological and haemodynamic measures of functional connectivity in target brain circuits (for example, hippocampal−prefrontal, thalamocortical), in rodents and man (WP1 and WP4); • link circuit-based measures of functional connectivity (WP1 and WP4), and their pharmacological modulation to specific behavioural paradigms (WP2); • confirm the importance of a circuit-based approach to evaluate established and novel compounds. The circuit-based work in NEWMEDS focused on brain circuits involving the prefrontal cortex (PFC), under the general working hypothesis that the function of this cortical system is crucial for mental health. The PFC controls emotion, cognition and behaviour via the top-down modulation of neuronal activity in other cortical and subcortical areas through the descending axons of pyramidal neurons. All these brain areas have reciprocal connection to the PFC with the exception of the basal ganglia, which feed back to the PFC via the thalamus, and the hippocampus, which itself has a unidirectional input to the PFC; this input is highly stress dependent and crucially involved in psychiatric diseases 1 . Furthermore, the activity of brainstem monoamine cell groups, which is sensitive to the action of antidepressant and antipsychotic drugs, is tightly controlled by the PFC. Additionally, intrinsic neuronal properties and synaptic transmission within the limbic brain microcircuits of the amygdala and hippocampus offer new opportunities for diverse therapeutic approaches.
Some key findings from this work include: • Thalamo-cortical circuits and their impact on PFC, hippocampus and amygdala were identified as a main target for the action of psychotomimetic agents [2] [3] [4] , such as the non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist phencyclidine (PCP). This may be of interest in depression, given the marked and rapid antidepressant actions of another NMDA receptor antagonist, ketamine, in treatmentresistant patients.
• When IMI-NEWMEDS was conceived, functional connectivity from rsfMRI, although widely established in humans, had not yet been back-translated to rodents. Work in WP4 showed that relevant functional networks, in many cases congruent with those observed in primates and humans, can be detected in both rat and mouse brains with paradigms optimized for reliability in a pharmaco-MRI context 5 . This provides translational biomarkers of brain circuit connectivity and its modulation.
• New technologies were explored among the partners and cross-validated to show how robust the tests were.
Cognitive end points were identified as a major unmet clinical need, and a battery of translational operant tests for rats and mice was designed and implemented by the academic leads and taken up by the EFPIA laboratories. The methylazoxymethanol (MAM)-E17 model of schizophrenia was found to have good cross-site reproducibility, but such high levels of variability within batches of animals that it was impractical for drug discovery. One of the EFPIA partners (Lilly) championed and developed oxygen amperometry as an animal surrogate of human fMRI.
• As a back-translational approach from clinical imaging of subjects from the Icelandic population with multiple copy number variants (CNVs), transgenic mice harbouring three CNVs associated with increased risk of schizophrenia (1q21, 15q13 and 22q11) were made available by Lundbeck (WP7). Studies with these mice supported the idea that it may be more effective to target drug action at downstream circuits where the effects of multiple genetic variants may converge 1, 4, 5 .
• Overall, NEWMEDS has indicated that the dogma that behavioural neuroscience is intrinsically unreliable is false; however, it does need sufficient support from electrophysiology and imaging.
Challenges, lessons and outlook
In addition to the general coordination and organization challenges typical of large consortia, there were more project-specific difficulties in harmonizing methodologies and data sharing, owing to the different experimental conditions in different set-ups (such as differences between groups regarding the use of anaesthesia). Similarly, difficulties in re-analysing historical data and comparing data between different set-ups could only be identified and resolved by specific meetings. Open discussion allowed rapid progress: for example, we discovered that we had been using the same electrode coordinates to define hippo campal−prefrontal pharmacology and agreed on the importance of this circuit as a potential link in psychiatry research 1 . This was extended in a rapidly evolving collaboration on imaging these brain circuits (in WP4) 5 . Putting together scientists from different EFPIA companies and academia enabled major synergies. We discovered that we had cross-validated each other's work, independently, which supported key concepts, particularly the precise brain circuits at risk. These frank discussions between researchers helped to move the field forward more rapidly, while not needlessly duplicating animal work. Where research is clearly precompetitive, there are immense benefits for open discussion between competitive companies, and this should be the rule rather than the exception. Furthermore, psychiatric drug discovery must make translational effects on brain circuits a priority.
